We recently compiled a list of 9 High-Growth Small-Cap Stocks That Are Profitable. Novavax, Inc. ranks second on our list of high-growth stocks.
TheFly reported on January 20 that BofA raised its price target on NVAX from $6 to $7, while maintaining an underperform rating. This update follows the company’s announcement of a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant in up to two infectious disease areas. Although BofA views the deal and upfront payment as positive signs of interest in Novavax, Inc.’s (NASDAQ: NVAX) technology, the company remains cautious about the development timeline of the licensed assets and continues to rate the stock as underperform.
Additionally, on January 21, NVAX saw unusually strong bullish options activity, with call trading occurring at approximately three times normal levels. Implied volatility jumped nearly eight points to over 71%, while the put/call ratio fell to 0.07, reflecting strong bullish positioning ahead of the company’s expected earnings later in February.
Novavax, Inc. (NASDAQ: NVAX) is an American biotechnology company that develops and commercializes innovative vaccines against serious infectious diseases using its recombinant protein platform and Matrix-M adjuvant. Its portfolio includes COVID‑19 and influenza vaccine candidates and combination vaccines, supported by strategic partnerships aimed at expanding global health impact.
While we recognize the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a hugely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the reshoring trend, check out our free report on the best AI stock in the short term.
READ NEXT: 12 Best Multibagger Stocks to Buy by 2026 And 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
